(0.82%) 5 059.63 points
(0.78%) 38 198 points
(1.36%) 15 818 points
(0.39%) $79.31
(5.28%) $2.03
(0.27%) $2 317.20
(0.69%) $26.93
(1.22%) $966.55
(-0.06%) $0.932
(-0.36%) $10.99
(-0.03%) $0.798
(-1.40%) $91.96
4 days till quarter result
(tns 2024-05-06)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada...
Stats | |
---|---|
Šios dienos apimtis | 2 249.00 |
Vidutinė apimtis | 2 921.00 |
Rinkos kapitalizacija | 6.32M |
EPS | $0 ( 2024-02-12 ) |
Kita pelno data | ( $0 ) 2024-05-06 |
Last Dividend | $0.500 ( 2008-08-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.50 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-28 | Riva Sheppard | Buy | 150 000 | Stock Option (right to buy) |
2023-11-28 | Kay Christina | Buy | 150 000 | Stock Option (right to buy) |
2023-11-28 | Masi Dina | Buy | 150 000 | Stock Option (right to buy) |
2023-03-20 | Kay E Gerald | Sell | 150 000 | Stock Option (right to buy) |
2023-03-20 | Kay E Gerald | Sell | 100 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
84.17 |
Last 98 transactions |
Buy: 38 374 999 | Sell: 953 334 |
Integrated BioPharma, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Integrated BioPharma, Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $50.67M |
Bruto pelnas: | $4.06M (8.01 %) |
EPS: | $-0.00110 |
FY | 2023 |
Pajamos: | $50.67M |
Bruto pelnas: | $4.06M (8.01 %) |
EPS: | $-0.00110 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Pajamos: | $56.25M |
Bruto pelnas: | $6.55M (11.65 %) |
EPS: | $0.130 |
Financial Reports:
No articles found.
Integrated BioPharma, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.500 | 2008-08-19 |
Last Dividend | $0.500 | 2008-08-19 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.500 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.55 | -- |
Div. Sustainability Score | 2.86 | |
Div.Growth Potential Score | 0.768 | |
Div. Directional Score | 1.816 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
FULO | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
EMYB | Ex Dividend Knight | 2023-06-29 | Annually | 0 | 0.00% | |
CBKM | Ex Dividend Knight | 2023-08-18 | Quarterly | 0 | 0.00% | |
TNCAF | Ex Dividend Junior | 2023-08-30 | Quarterly | 0 | 0.00% | |
RSKIA | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
NIPNF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
FMCB | Ex Dividend Knight | 2023-06-08 | Semi-Annually | 0 | 0.00% | |
CSBB | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
WCRS | Ex Dividend Junior | 2023-08-21 | Quarterly | 0 | 0.00% | |
BABB | Ex Dividend King | 2023-09-27 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.00615 | 1.500 | -0.123 | -0.185 | [0 - 0.5] |
returnOnAssetsTTM | -0.0150 | 1.200 | -0.499 | -0.599 | [0 - 0.3] |
returnOnEquityTTM | -0.0205 | 1.500 | -1.339 | -2.01 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.93 | 0.800 | 0.372 | 0.298 | [1 - 3] |
quickRatioTTM | 0.765 | 0.800 | -0.203 | -0.162 | [0.8 - 2.5] |
cashRatioTTM | 0.125 | 1.500 | -0.414 | -0.621 | [0.2 - 2] |
debtRatioTTM | 0.0884 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -27.32 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.00942 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.00829 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.122 | -1.500 | 9.51 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0535 | 1.000 | -2.44 | -2.44 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0109 | 1.000 | -2.22 | -2.22 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.125 | 1.000 | -0.419 | -0.419 | [0.2 - 2] |
assetTurnoverTTM | 2.43 | 0.800 | 10.00 | 8.00 | [0.5 - 2] |
Total Score | 2.86 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -16.42 | 1.000 | -1.759 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0205 | 2.50 | -0.861 | -2.01 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.00829 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.00942 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.102 | 1.500 | -4.01 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.00453 | 1.000 | -2.39 | 0 | [0.1 - 0.5] |
Total Score | 0.768 |
Integrated BioPharma,
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.